Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 12, 2004; DOI: 10.1124/jpet.103.059824
0022-3565/04/3091-102-108$20.00
JPET 309:102-108, 2004
INFLAMMATION AND IMMUNOPHARMACOLOGY
Inverse Agonist Activity of Selected Ligands of the Cysteinyl-Leukotriene Receptor 1
Denis J. Dupré,
Christian Le Gouill,
Denis Gingras,
Marek Rola-Pleszczynski, and
Jana Sta
ková
Immunology Division, Department of Pediatrics, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Québec, Canada
Cysteinyl leukotrienes (CysLTs) are associated with several inflammatory processes, including asthma. Due to this association, considerable effort has been invested in the development of antagonists to the CysLT receptors (CysLT1R). Many of these molecules have been shown to specifically interact with CysLT1R, but little is known about their impact on the conformation of the receptor and its activity. We were especially interested in possible inverse agonist activity of the antagonists. Using a constitutively active mutant (N106A) of the human CysLT1R and the wild-type (WT) receptor coexpressed with the G
q subunit of the trimeric G protein, we were able to address this issue with ligands commonly used in therapy. We demonstrated that some of these molecules are inverse agonists, whereas others act as partial agonists. In cells expressing the CysLT1R mutant N106A exposed to Montelukast, Zafirlukast, or 3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid (MK571), the basal inositol phosphate production was reduced by 53 ± 6, 44 ± 3, and 54 ± 4%, respectively. On the other hand, 6(R)-(4-carboxyphenylthio)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)-eicosatetraenoic acid (BayU9773) and 1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazole-5-YL)-butoxy]-phenyl ethanone] (LY171883) acted as partial agonists and
-pentyl-3-[2-quinolinylmethoxy] benzyl alcohol (REV 5901) as a neutral antagonist. However, in cells expressing CysLT1R and G
q, all antagonists used had inverse agonist activity. The decrease in basal inositol phosphate production by ligands with inverse agonist activity could be inhibited by a more neutral antagonist, confirming the specificity of the reaction. We demonstrate here that Montelukast, MK571, and Zafirlukast can act as inverse agonists on the human CysLT1 receptor.
Received September 10, 2003;
accepted December 18, 2003.
Address correspondence to: Dr. Jana Stankova, Immunology Division, Department of Pediatrics, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Québec, J1H 5N4 Canada. E-mail: jana.stankova{at}usherbrooke.ca
This article has been cited by other articles:

|
 |

|
 |
 
K. Parameswaran, K. Radford, A. Fanat, J. Stephen, C. Bonnans, B. D. Levy, L. J. Janssen, and P. G. Cox
Modulation of Human Airway Smooth Muscle Migration by Lipid Mediators and Th-2 Cytokines
Am. J. Respir. Cell Mol. Biol.,
August 1, 2007;
37(2):
240 - 247.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Oliveira, C. M. Costa-Neto, C. R. Nakaie, S. Schreier, S. I. Shimuta, and A. C. M. Paiva
The Angiotensin II AT1 Receptor Structure-Activity Correlations in the Light of Rhodopsin Structure
Physiol Rev,
April 1, 2007;
87(2):
565 - 592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Ding, S. Kim, and S. P. Kunapuli
Identification of a Potent Inverse Agonist at a Constitutively Active Mutant of Human P2Y12 Receptor
Mol. Pharmacol.,
January 1, 2006;
69(1):
338 - 345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Parhamifar, B. Jeppsson, and A. Sjolander
Activation of cPLA2 is required for leukotriene D4-induced proliferation in colon cancer cells
Carcinogenesis,
November 1, 2005;
26(11):
1988 - 1998.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.